A detailed history of Raymond James & Associates transactions in Exelixis, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 239,661 shares of EXEL stock, worth $6.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
239,661
Previous 109,856 118.16%
Holding current value
$6.89 Million
Previous $2.47 Million 151.99%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$21.96 - $27.6 $2.85 Million - $3.58 Million
129,805 Added 118.16%
239,661 $6.22 Million
Q2 2024

Jul 19, 2024

BUY
$20.34 - $23.73 $27,011 - $31,513
1,328 Added 1.22%
109,856 $2.47 Million
Q1 2024

Apr 22, 2024

SELL
$20.17 - $23.93 $102,927 - $122,114
-5,103 Reduced 4.49%
108,528 $2.58 Million
Q4 2023

Jan 16, 2024

BUY
$19.25 - $24.13 $80,561 - $100,984
4,185 Added 3.82%
113,631 $2.73 Million
Q3 2023

Oct 24, 2023

SELL
$19.04 - $22.74 $545,553 - $651,569
-28,653 Reduced 20.75%
109,446 $2.39 Million
Q2 2023

Jul 25, 2023

SELL
$18.17 - $20.48 $245,458 - $276,664
-13,509 Reduced 8.91%
138,099 $2.64 Million
Q1 2023

Apr 14, 2023

BUY
$16.3 - $19.41 $191,052 - $227,504
11,721 Added 8.38%
151,608 $2.94 Million
Q4 2022

Feb 08, 2023

SELL
$14.96 - $17.39 $37,519 - $43,614
-2,508 Reduced 1.76%
139,887 $2.24 Million
Q3 2022

Oct 25, 2022

BUY
$15.68 - $22.27 $920,949 - $1.31 Million
58,734 Added 70.2%
142,395 $2.23 Million
Q2 2022

Aug 12, 2022

SELL
$17.44 - $23.16 $261,024 - $346,635
-14,967 Reduced 15.18%
83,661 $1.74 Million
Q1 2022

May 11, 2022

BUY
$17.03 - $22.67 $103,951 - $138,377
6,104 Added 6.6%
98,628 $2.24 Million
Q4 2021

Feb 08, 2022

SELL
$15.84 - $21.88 $163,722 - $226,151
-10,336 Reduced 10.05%
92,524 $1.69 Million
Q3 2021

Nov 02, 2021

BUY
$16.3 - $21.14 $921,145 - $1.19 Million
56,512 Added 121.93%
102,860 $2.17 Million
Q2 2021

Aug 11, 2021

SELL
$17.95 - $25.56 $14,377 - $20,473
-801 Reduced 1.7%
46,348 $844,000
Q1 2021

May 14, 2021

SELL
$20.53 - $25.22 $34,059 - $41,839
-1,659 Reduced 3.4%
47,149 $1.07 Million
Q4 2020

Feb 12, 2021

BUY
$18.39 - $24.8 $16,808 - $22,667
914 Added 1.91%
48,808 $980,000
Q3 2020

Nov 04, 2020

SELL
$20.67 - $26.94 $51,364 - $66,945
-2,485 Reduced 4.93%
47,894 $1.17 Million
Q2 2020

Jul 28, 2020

BUY
$16.46 - $27.42 $104,422 - $173,952
6,344 Added 14.41%
50,379 $1.2 Million
Q1 2020

Apr 21, 2020

SELL
$14.46 - $21.8 $1.05 Million - $1.58 Million
-72,347 Reduced 62.16%
44,035 $758,000
Q4 2019

Feb 12, 2020

SELL
$15.15 - $18.89 $41,692 - $51,985
-2,752 Reduced 2.31%
116,382 $2.05 Million
Q3 2019

Nov 07, 2019

SELL
$17.68 - $22.65 $523,858 - $671,119
-29,630 Reduced 19.92%
119,134 $2.11 Million
Q2 2019

Aug 06, 2019

SELL
$18.93 - $24.75 $3.75 Million - $4.9 Million
-197,851 Reduced 57.08%
148,764 $3.18 Million
Q1 2019

May 06, 2019

BUY
$19.6 - $24.76 $1.94 Million - $2.46 Million
99,163 Added 40.07%
346,615 $8.25 Million
Q4 2018

Feb 11, 2019

SELL
$13.65 - $21.8 $40,499 - $64,680
-2,967 Reduced 1.18%
247,452 $4.87 Million
Q3 2018

Nov 14, 2018

BUY
$15.87 - $22.4 $2.75 Million - $3.88 Million
173,104 Added 223.89%
250,419 $4.44 Million
Q2 2018

Aug 14, 2018

BUY
$18.56 - $22.45 $532,931 - $644,629
28,714 Added 59.08%
77,315 $1.66 Million
Q1 2018

May 14, 2018

SELL
$22.15 - $31.89 $699,851 - $1.01 Million
-31,596 Reduced 39.4%
48,601 $1.08 Million
Q4 2017

Feb 14, 2018

BUY
$24.23 - $30.93 $1.25 Million - $1.59 Million
51,431 Added 178.79%
80,197 $2.44 Million
Q3 2017

Nov 13, 2017

BUY
$23.35 - $29.24 $671,686 - $841,117
28,766
28,766 $697,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $9.25B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.